Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Adaptimmune Therapeutics plc ADAP

Healthcare Biotechnology
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. The Company is focused on providing cell therapies to people with cancer. Its engineered T-cell receptor (TCR) platform enables the engineering of T-cells to target and destroy cancers across multiple solid tumor types. Its cell therapy candidates include TCR T-cells and TruC T-cells. Its product candidates include... see more

Recent & Breaking News (NDAQ:ADAP)

Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK

Newsfile 7 days ago

First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)

Newsfile December 2, 2024

Adaptimmune Reports Q3 2024 Financial and Business Updates

Newsfile November 13, 2024

Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial

Newsfile November 13, 2024

Adaptimmune to Participate in Scientific and Medical Conferences this November and December

Newsfile November 5, 2024

Adaptimmune to Report Q3 2024 Financial and Business Updates on Wednesday, November 13, 2024

Newsfile October 31, 2024

Adaptimmune to Participate in Two Bank Conferences this September

Newsfile August 28, 2024

Adaptimmune Reports Q2 2024 Financial and Business Updates

Newsfile August 12, 2024

Adaptimmune to Report Q2 2024 Financial and Business Updates on Monday, August 12, 2024

Newsfile August 5, 2024

Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor

Business Wire August 1, 2024

Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise

Newsfile June 3, 2024

Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications

Newsfile May 30, 2024

Adaptimmune Reports Q1 2024 Financial and Business Updates

Newsfile May 15, 2024

Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital

Newsfile May 15, 2024

Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024

Newsfile May 1, 2024

Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated

Newsfile April 12, 2024

Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet

Newsfile March 27, 2024

Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates

Newsfile March 6, 2024

Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise

Newsfile February 27, 2024

Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024

Newsfile February 21, 2024